SEARCH

SEARCH BY CITATION

References

  • 1
    Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599606.
  • 2
    De Berker D, Mcgregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222230.
  • 3
    Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis – an update. Br J Dermatol 2007; 157(Suppl. 2): 1820.
  • 4
    Marks R. Who benefits from calling a solar keratosis a squamous cell carcinoma? Br J Dermatol 2006; 155: 2326.
  • 5
    Loven K, Stein L, Furst K, et al . Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 9901000.
  • 6
    Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006; 55: 537538.
  • 7
    Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9: 209214.
  • 8
    Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006; 126: 12511255.
  • 9
    HigginsJPT, GreenS (eds) Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated, February 2008]. The Cochrane Collaboration, 2008. Available from http://www.cochrane-handbook.org[accessed on 27 March 2008].
  • 10
    The Nordic Cochrane Centre. Review Manager (Revman) [Computer Program], Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, 2003.
  • 11
    Hantash BM, Stewart DB, Cooper ZA, et al . Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006; 142: 976982.
  • 12
    Jorizzo J, Weiss J, Furst K, et al . Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004; 140: 813816.
  • 13
    Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144147.
  • 14
    Krawtchenko N, Roewert-Huber J, Ulrich M, et al . A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl. 2): 3440.
  • 15
    Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5: 156159.
  • 16
    Ostertag JU, Quaedvlieg PJF, Van Der Geer S, et al . A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006; 38: 731739.
  • 17
    Kurwa HA, Yong-Gee SA, Seed PT, et al . A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41(3 Part 1): 414418.
  • 18
    Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol 1987; 116: 549552.
  • 19
    Jury CS, Ramraka-Jones VS, Gudi V, et al . A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol 2005; 153: 808810.
  • 20
    Jorizzo J, Stewart D, Bucko A, et al . Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002; 70: 335339.
  • 21
    Weiss J, Menter A, Hevia O, et al . Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70 (2 Suppl): 22– 29.
  • 22
    Smith S, Piacquadio D, Morhenn V, et al . Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003; 2: 629635.
  • 23
    Valeant Pharmaceutical North America. EFUDEX® (Fluorouracil) Topical Solutions and Cream: Product Information. Costa Mesa, CA: Valeant Pharmaceutical North America, 2005.
  • 24
    Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273277.
  • 25
    Valeant Pharmaceuticals. EFUDEX® (Fluorouracil) Website. URL http://www.efudex.com/[accessed on 15 December 2007].
  • 26
    Pincus T, Tugwell P. Shouldn't standard rheumatology clinical care be evidence-based rather than eminence-based, eloquence-based, or elegance-based? J Rheumatol 2007; 34: 14.